Boron delivery agents for neutron capture therapy of cancer

Cancer Communications

Table 1 Examples of new low- and high-molecular weight boron delivery agents currently under evaluation

Boric acid [139]	Boronated VEGF [64]
Boron-containing immunoliposomes [101, 103] and liposomes [90, 91, 93, 94, 102, 104, 105]	Boronated unnatural amino acids [57, 61,62,63,64]
	Boron-containing nanoparticles [140,141,142]
Boron-containing Lipiodol [143,144,145]	Carboranyl nucleosides [70, 146]
Boron nitride nanotubes [147,148,149]	Carboranyl porphyrazines [139]
Boronated co-polymers [85, 86]	Carboranyl thymidine analogues [70,71,72]
Boronated cyclic peptides [62]	Decaborone (GB10) [131, 143]
Boronated DNA intercalators [77]	Dodecaborate cluster lipids and cholesterol derivatives [144]
Boronated EGF [82, 83] and anti-EGFR MoAbs [67,68,69, 150]	Dodecahydro-closo-dodecaborate clusters [144]
Boronated polyamines [147, 151]	Linear and cyclic peptides [65]
Boronated porphyrins [74,75,76,77,78]	Polyanionic polymers [86]
Boronated sugars [152]	Transferrin-polyethylene glycol liposomes [140]

The delivery agents are listed alphabetically and not in any order indicating their potential usefulness for BNCT. None of these agents have been evaluated clinically
BNCT boron neutron capture therapy, EGF epidermal growth factor, EGFR epidermal growth factor receptor, MoAbs monoclonal antibodies, VEGF vascular endothelial growth factor

ISSN: 2523-3548